Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 127.66 Billion KRW | 13.93% |
| 2022 | 111.99 Billion KRW | 22.14% |
| 2021 | 91.69 Billion KRW | 33.51% |
| 2020 | 68.68 Billion KRW | -2.69% |
| 2019 | 70.58 Billion KRW | 3.6% |
| 2018 | 68.13 Billion KRW | -5.77% |
| 2017 | 72.3 Billion KRW | -7.72% |
| 2016 | 78.35 Billion KRW | -4.96% |
| 2015 | 82.44 Billion KRW | 0.9% |
| 2014 | 81.71 Billion KRW | 15.57% |
| 2013 | 70.7 Billion KRW | 8.51% |
| 2012 | 65.15 Billion KRW | 0.49% |
| 2011 | 64.83 Billion KRW | -2.88% |
| 2010 | 66.75 Billion KRW | -4.48% |
| 2009 | 69.88 Billion KRW | 8.19% |
| 2008 | 64.59 Billion KRW | 6.37% |
| 2007 | 60.72 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 21.83 Billion KRW | -7.86% |
| 2024 Q1 | 23.69 Billion KRW | -32.16% |
| 2023 Q1 | 30.76 Billion KRW | -3.91% |
| 2023 Q2 | -31.59 Billion KRW | -202.71% |
| 2023 Q4 | 34.93 Billion KRW | 214.6% |
| 2023 Q3 | -30.48 Billion KRW | 3.53% |
| 2023 FY | 127.59 Billion KRW | 13.93% |
| 2022 Q2 | 22.59 Billion KRW | -6.72% |
| 2022 Q4 | 32.01 Billion KRW | -4.18% |
| 2022 FY | 111.99 Billion KRW | 22.14% |
| 2022 Q3 | 33.41 Billion KRW | 47.9% |
| 2022 Q1 | 24.22 Billion KRW | -14.23% |
| 2021 Q1 | 19.37 Billion KRW | 23.24% |
| 2021 Q2 | 18.53 Billion KRW | -4.36% |
| 2021 Q3 | 25.54 Billion KRW | 37.85% |
| 2021 Q4 | 28.23 Billion KRW | 10.54% |
| 2021 FY | 91.69 Billion KRW | 33.51% |
| 2020 Q4 | 15.72 Billion KRW | -13.63% |
| 2020 Q1 | 17.05 Billion KRW | -12.39% |
| 2020 FY | 68.68 Billion KRW | -2.69% |
| 2020 Q3 | 18.2 Billion KRW | 2.83% |
| 2020 Q2 | 17.7 Billion KRW | 3.8% |
| 2019 Q3 | 16.04 Billion KRW | -10.43% |
| 2019 Q2 | 17.9 Billion KRW | 4.35% |
| 2019 Q1 | 17.16 Billion KRW | -10.45% |
| 2019 Q4 | 19.46 Billion KRW | 21.35% |
| 2019 FY | 70.58 Billion KRW | 3.6% |
| 2018 Q4 | 19.16 Billion KRW | 19.41% |
| 2018 FY | 68.13 Billion KRW | -5.77% |
| 2018 Q3 | 16.05 Billion KRW | -6.87% |
| 2018 Q2 | 17.23 Billion KRW | 9.89% |
| 2018 Q1 | 15.68 Billion KRW | -27.76% |
| 2017 Q2 | 16.78 Billion KRW | 0.53% |
| 2017 Q1 | 16.69 Billion KRW | 8.6% |
| 2017 FY | 72.3 Billion KRW | -7.72% |
| 2017 Q4 | 21.7 Billion KRW | 26.79% |
| 2017 Q3 | 17.12 Billion KRW | 2.03% |
| 2016 Q3 | 24.06 Billion KRW | 21.35% |
| 2016 Q4 | 15.36 Billion KRW | -36.13% |
| 2016 Q1 | 19.09 Billion KRW | -2.24% |
| 2016 FY | 78.35 Billion KRW | -4.96% |
| 2016 Q2 | 19.83 Billion KRW | 3.85% |
| 2015 FY | 82.44 Billion KRW | 0.9% |
| 2015 Q1 | 20.57 Billion KRW | -15.76% |
| 2015 Q4 | 19.53 Billion KRW | 2.68% |
| 2015 Q3 | 19.02 Billion KRW | -18.43% |
| 2015 Q2 | 23.32 Billion KRW | 13.37% |
| 2014 Q4 | 24.42 Billion KRW | 24.16% |
| 2014 Q1 | 18.66 Billion KRW | -12.37% |
| 2014 FY | 81.71 Billion KRW | 15.57% |
| 2014 Q2 | 18.95 Billion KRW | 1.51% |
| 2014 Q3 | 19.67 Billion KRW | 3.8% |
| 2013 Q2 | 18.1 Billion KRW | 15.28% |
| 2013 Q3 | 15.59 Billion KRW | -13.88% |
| 2013 Q4 | 21.3 Billion KRW | 36.65% |
| 2013 FY | 70.7 Billion KRW | 8.51% |
| 2013 Q1 | 15.7 Billion KRW | -15.68% |
| 2012 Q4 | 18.62 Billion KRW | 9.68% |
| 2012 FY | 65.15 Billion KRW | 0.49% |
| 2012 Q1 | 14.63 Billion KRW | 0.0% |
| 2012 Q2 | 14.24 Billion KRW | -2.71% |
| 2012 Q3 | 16.97 Billion KRW | 19.23% |
| 2011 Q2 | 15.38 Billion KRW | 3.55% |
| 2011 Q3 | 16.68 Billion KRW | 8.44% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 64.83 Billion KRW | -2.88% |
| 2011 Q1 | 14.85 Billion KRW | 0.0% |
| 2010 Q1 | 13.55 Billion KRW | 0.0% |
| 2010 FY | 66.75 Billion KRW | -4.48% |
| 2010 Q3 | 14.94 Billion KRW | 0.58% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 14.86 Billion KRW | 9.67% |
| 2009 Q1 | 16.75 Billion KRW | 0.0% |
| 2009 Q2 | 18.6 Billion KRW | 11.06% |
| 2009 Q3 | 16.23 Billion KRW | -12.74% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 69.88 Billion KRW | 8.19% |
| 2008 Q3 | 16.41 Billion KRW | 1.75% |
| 2008 Q1 | 14.2 Billion KRW | 0.0% |
| 2008 FY | 64.59 Billion KRW | 6.37% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 16.13 Billion KRW | 13.59% |
| 2007 Q3 | 14.91 Billion KRW | 2.05% |
| 2007 Q2 | 14.61 Billion KRW | 9.87% |
| 2007 Q1 | 13.3 Billion KRW | 0.0% |
| 2007 FY | 60.72 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -170.178% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 57.157% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 54.148% |
| HANDOK Inc. | 153.76 Billion KRW | 16.973% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -84.457% |
| Yuhan Corporation | 489.94 Billion KRW | 73.942% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 58.408% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -205.506% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 79.104% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -77.36% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 26.689% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -218.75% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -36.47% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -11.283% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -170.178% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -200.599% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -70.114% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -117.702% |
| JW Holdings Corporation | 301.25 Billion KRW | 57.621% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 51.076% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 68.759% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 46.562% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -86.894% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -94.17% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 27.015% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -170.178% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 48.752% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 77.219% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 46.562% |
| Yuhan Corporation | 489.94 Billion KRW | 73.942% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 34.077% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -83.78% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -127.851% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 46.562% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -1.01% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -7.999% |
| CKD Bio Corp. | 25.19 Billion KRW | -406.71% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 42.491% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 22.678% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -92.223% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 63.597% |
| Boryung Corporation | 285.16 Billion KRW | 55.229% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -45.838% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 26.689% |
| JW Lifescience Corporation | 20.26 Billion KRW | -530.106% |